Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus coagulans + CGI314
- Development stage
- Preclinical
- Lead developer
- Deerland Enzymes
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans + CGI314 is a combination probiotic product containing a specific strain of Bacillus coagulans known as CGI314. Bacillus coagulans (also referred to as Weizmannia coagulans) is a spore-forming lactic acid bacterium used as a probiotic to support gut health. The strain designation "CGI314" refers to a particular isolate within the B. coagulans species, which may have unique properties or efficacy profiles compared to other strains. Probiotics like B. coagulans are believed to exert their effects by modulating the intestinal microbiota, inhibiting pathogenic bacteria, and supporting digestive function through lactic acid production and spore germination in the gut[1][5]. This combination is primarily investigated for gastrointestinal conditions such as irritable bowel syndrome (IBS), constipation, diarrhea, dysbiosis, and related symptoms[1][2][3][5]. The mechanism of action involves competitive inhibition of harmful bacteria and restoration of healthy microbial balance in the intestines.
- Other names
- Bacillus coagulans CGI314Weizmannia coagulans CGI314
02
Targets
Shigella spp. (Shigella species)
Beyond the preview
Go deeper on bacillus coagulans + CGI314.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus coagulans + CGI314.